Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Key Points

• This research aims to compare the effects of metabolic bariatric surgery and semaglutide on liver and extrahepatic health outcomes in patients with metabolic dysfunction-associated liver disease and type 2 diabetes.
• Compared metabolic bariatric surgery with semaglutide in patients with metabolic dysfunction and type 2 diabetes
• Evaluated hepatic and extrahepatic outcomes including cirrhosis and heart failure
• Utilized liver assessment to inform treatment decisions
• Increased risk of metabolic adverse liver outcomes was noted with metabolic bariatric surgery compared to semaglutide
• Metabolic bariatric surgery showed protective effects against major adverse cardiovascular events
• First diagnosis of cirrhosis and heart failure was more frequently observed with metabolic bariatric surgery

Abstract